Drug Trial Radar · NCT00043303
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
Last checked: Nov 20, 2026Latest source record: Nov 1, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
502
Actual
Start
Sep 2001
Primary completion
Not stated
Study completion Nov 2003
Sponsor
- Lead sponsor
- InterMuneIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2002
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to test the safety and effectiveness of Interferon gamma-1b (IFN-g 1b) injected subcutaneously (under the skin) for the treatment of advanced liver fibrosis and cirrhosis in patients with chronic hepatitis C infections. IFN-g 1b is not currently approved for the treatment of liver fibrosis.
Conditions
- Liver Fibrosis
- Cirrhosis
Interventions
interferon gamma-1bDrug
100 or 200 mcg, SQ, 3x per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ishak fibrosis scoreTime frame: 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.